Stéphane Culine

8.7k total citations · 2 hit papers
109 papers, 5.4k citations indexed

About

Stéphane Culine is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stéphane Culine has authored 109 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 41 papers in Surgery and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stéphane Culine's work include Testicular diseases and treatments (20 papers), Bladder and Urothelial Cancer Treatments (18 papers) and Prostate Cancer Treatment and Research (14 papers). Stéphane Culine is often cited by papers focused on Testicular diseases and treatments (20 papers), Bladder and Urothelial Cancer Treatments (18 papers) and Prostate Cancer Treatment and Research (14 papers). Stéphane Culine collaborates with scholars based in France, United States and Spain. Stéphane Culine's co-authors include Yves Fradet, Dean F. Bajorin, Nicholas J. Vogelzang, Howard Gurney, Cora N. Sternberg, Daniel P. Petrylak, Toni K. Choueiri, David J. Vaughn, Lawrence Fong and Ronald de Wit and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Stéphane Culine

106 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

2017 2.4k citations Joaquim Bellmunt, Ronald de Wit et al. New England Journal of Medicine profile →
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

2019 306 citations Yves Fradet, Joaquim Bellmunt et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Stéphane Culine

Since Specialization

Citations

This map shows the geographic impact of Stéphane Culine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Culine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Culine more than expected).

Fields of papers citing papers by Stéphane Culine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Culine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Culine. The network helps show where Stéphane Culine may publish in the future.

Co-authorship network of co-authors of Stéphane Culine

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Culine. A scholar is included among the top collaborators of Stéphane Culine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Culine. Stéphane Culine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma breakdown → 2017 ·New England Journal of Medicine ·Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin	2374
2	Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc) 2017 ·Annals of Oncology ·Daniel P. Petrylak, Nicholas J. Vogelzang, Yves Fradet, Dean F. Bajorin, Ronald de Wit, David J. Vaughn, Jia-Lin Lee, Lawrence Fong, José A. Martínez-Climent, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, E. Jensen, Markus Puhlmann, Rodolfo F. Perini, Joaquim Bellmunt, Toni K. Choueiri	5
3	Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial 2017 ·Annals of Oncology ·Ronald de Wit, David J. Vaughn, Yves Fradet, Jia-Lin Lee, Lawrence Fong, Nicholas J. Vogelzang, José A. Martínez-Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Markus Puhlmann, Rodolfo F. Perini, Joaquim Bellmunt, Dean F. Bajorin	6
4	Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study 2016 ·Clinical Genitourinary Cancer ·(unknown), Réza Elaidi, Mustafa Özgüroğlu, (unknown), Hélène Gauthier, Stéphane Culine, Armelle Caty, (unknown), Édouard Auclin, (unknown), Pierre Combe, Éric Tartour, Stéphane Oudard	8
5	Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort 2016 ·Clinical Genitourinary Cancer ·Damien Pouessel, Sylvie Bastuji‐Garin, Nadine Houédé, Dimitri Vordos, Yohann Loriot, Christine Chevreau, Emmanuel Sevin, Philippe Beuzeboc, Alexandre de la Taille, Aurélie Le Thuaut, Yves Allory, Stéphane Culine	11
6	To Treat or Not to Treat Metastatic Cancer Patients with Poor Performance Status: a Prospective Experience 2016 ·Pathology & Oncology Research ·Tamás Kullmann, Hélène Gauthier, (unknown), Damien Pouessel, Christine Le Maignan, Jean-Louis Misset, Stéphane Culine	4
7	Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer 2012 ·Journal of Geriatric Oncology ·Stéphane Culine, C. Terret, Didier Cupissol, Gilles Romieu, Michel Fabbro, Damien Pouessel, Jean‐Pierre Droz, Sophie Gourgou	6
8	Cancers du rein avancés en situations particulières. Comment les traiter? 2010 ·Bulletin du Cancer ·Damien Pouessel, J.-J. Patard, Stéphane Culine	1
9	Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor 2008 ·Annals of Oncology ·(unknown), Patricia Pautier, Pierre Duvillard, A. Rey, Philippe Morice, Christine Haie-Méder, Pierre Kerbrat, Stéphane Culine, Frédéric Troalen, C. Lhommé	63
10	Prognostic factors for first recurrence in patients with retroperitoneal sarcoma 2006 ·Urologic Oncology Seminars and Original Investigations ·C. Avancès, Nicolas Mottet, (unknown), (unknown), Isabelle Serre, Stéphane Culine	22
11	Simultaneous determination of dexamethasone and 6β-hydroxydexamethasone in urine using solid-phase extraction and liquid chromatography: applications to in vivo measurement of cytochrome P450 3A4 activity 2004 ·Journal of Chromatography B ·(unknown), Françoise Bressolle, Isabelle Solassol, (unknown), Stéphane Culine, Frédéric Pinguet	14
12	Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer 2004 ·British Journal of Cancer ·Jacques Bonneterre, Véronique Dièras, M. Tubiana-Hulin, Philippe Bougnoux, (unknown), T. Delozier, (unknown), Stéphane Culine, (unknown), Belguendouz Bendahmane	44
13	Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support 2004 ·Cancer ·Stéphane Culine, Gilles Romieu, Michel Fabbro, Catherine Becht, Didier Cupissol, (unknown), Jean‐Pierre Bleuse, (unknown), Sophie Gourgou	4
14	Stage I non-seminomatous germ-cell tumours of the testis 2001 ·European Journal of Cancer ·J. Alexandre, Karim Fizazi, C Mahé, Stéphane Culine, Jean‐Pierre Droz, Christine Théodore, Marie‐José Terrier‐Lacombe	48
15	The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients 2000 ·European Journal of Cancer ·Fabrice André, Karim Fizazi, Stéphane Culine, Jean‐Pierre Droz, Pierre Taupin, C. Lhommé, Marie‐José Terrier‐Lacombe, Christine Théodore	156
16	Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy 1999 ·Annals of Oncology ·Stéphane Culine, Michel Fabbro, Marc Ychou, Gilles Romieu, Didier Cupissol, H Pujol	20
17	Carcinomas of unknown primary site 1998 ·Bulletin du Cancer ·Karim Fizazi, Stéphane Culine	2
18	Adult granulosa-cell tumor of the ovary: a retrospective study of 45 cases 1997 ·International Journal of Gynecological Cancer ·Patricia Pautier, C. Lhommé, Stéphane Culine, Pierre Duvillard, G Michel, Jean‐Michel Bidart, A Gerbaulet, Jean‐Pierre Droz	42
19	Cisplatin-Based Chemotherapy in Dysgerminoma of the Ovary: Thirteen-Year Experience at the Institut Gustave Roussy 1995 ·Gynecologic Oncology ·Stéphane Culine, Catherine Lhommé, Joseph Kattan, Pierre Duvillard, Guy Michel, A Gerbaulet, J.P. Droz	20
20	Hepatocellular Carcinoma During Hormonotherapy for Prostatic Cancer 1994 ·American Journal of Clinical Oncology ·Joseph Kattan, Alan Spatz, Stéphane Culine, Marie‐José Terrier‐Lacombe, Dominique Elias, Jean‐Pierre Droz	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact